Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

[1] Detterbeck FC(2017)The eighth edition lung Cancer stage classification Chest 151 193-203

[2] Boffa DJ(1991)Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience J Clin Oncol 9 1618-1626

[3] Kim AW(2007)Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era Ann Thorac Surg 83 231-234

[4] Tanoue LT(2014)Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer J Thorac Oncol 9 1426-1433

[5] Albain KS(2008)Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol 26 4617-4625

[6] Crowley JJ(2017)Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter Int J Radiat Oncol Biol Phys 98 419-427

[7] LeBlanc M(2016)Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study Lancet Oncol 17 1672-1682

[8] Livingston RB(2012)Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer Pulm Med 2012 396592-1961

[9] De Pas TM(2018)Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous Oligometastases treated in a prospective phase II trial (NCT 01282450) J Thorac Oncol 13 1958-422

[10] de Braud F(2017)Definitive stereotactic body radiotherapy (SBRT) for Extracranial Oligometastases: an international survey of >1000 radiation oncologists Am J Clin Oncol 40 418-1959

[1] Detterbeck FC(2017)The eighth edition lung Cancer stage classification Chest 151 193-203

[2] Boffa DJ(1991)Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience J Clin Oncol 9 1618-1626

[3] Kim AW(2007)Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era Ann Thorac Surg 83 231-234

[4] Tanoue LT(2014)Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer J Thorac Oncol 9 1426-1433

[5] Albain KS(2008)Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol 26 4617-4625

[6] Crowley JJ(2017)Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter Int J Radiat Oncol Biol Phys 98 419-427

[7] LeBlanc M(2016)Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study Lancet Oncol 17 1672-1682

[8] Livingston RB(2012)Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer Pulm Med 2012 396592-1961

[9] De Pas TM(2018)Progression-free survival and overall survival beyond 5 years of NSCLC patients with synchronous Oligometastases treated in a prospective phase II trial (NCT 01282450) J Thorac Oncol 13 1958-422

[10] de Braud F(2017)Definitive stereotactic body radiotherapy (SBRT) for Extracranial Oligometastases: an international survey of >1000 radiation oncologists Am J Clin Oncol 40 418-1959